定量分析支持淀粉样蛋白PET对疑难病例的视觉评估:AMYPAD诊断与患者管理研究结果
本研究纳入AMYPAD诊断与患者管理研究全部741例有基线淀粉样蛋白PET定量数据的参与者,局部阅片者视觉评估与Centiloid分类高度一致(κ=0.85,92.3%一致)。在101例疑难子样本中,披露定量结果后5名中心阅片者间一致性从κ=0.65提升至κ=0.74,阅片信心显著增加(基线均值4.0 vs 披露后4.34,P<0.001)。
要点
- 全队列局部阅片视觉评估与Centiloid状态高度一致(κ=0.85,92.3%一致)。
- 疑难子样本中披露定量结果后阅片者间一致性从κ=0.65升至κ=0.74。
- 披露定量结果后阅片信心显著增加(均值4.0 vs 4.34,P<0.001)。
核心结论
- 在富集疑难淀粉样蛋白PET病例的临床研究中,定量分析对视觉评估具有支持价值。
- 披露定量结果后,阅片者间一致性和阅片信心均显著改善。
- 考虑到抗淀粉样蛋白治疗采用Centiloid指标进行试验入组和靶点 Engagement,这些结果具有重要意义。
- 定量分析可支持以高确定性判定淀粉样蛋白β状态,这是治疗启动的重要因素。
研究设计与样本
- 纳入AMYPAD诊断与患者管理研究全部有基线淀粉样蛋白PET定量数据的参与者(n=741)。
- 定量采用仅PET的AmyPype流程,提供全局Centiloid和区域z评分。
- 视觉评估由局部阅片者对全队列完成。
- 从总队列中选取85例局部阅片者视觉评估与Centiloid分类( cutoff=21)不一致或局部阅片者信心低(5分制≤3分)的病例,另选各示踪剂一致阴性(n=8)和阳性(n=8)扫描,共101例([18F]flutemetamol n=48;[18F]florbetaben n=53)。
- 由5名认证独立中心阅片者在披露定量结果前后记录视觉评估及相应信心。
主要发现
- 全AMYPAD诊断与患者管理研究队列中,局部阅片者总体评估与Centiloid状态高度一致(κ=0.85,92.3%一致)。
- 各疾病阶段一致:主观认知下降-plus κ=0.82,92.3%一致;轻度认知障碍 κ=0.80,89.8%一致;痴呆 κ=0.87,94.6%一致。
- 疑难子样本所有中心阅片者评估中,全局Centiloid和区域z评分分别有70.3%和49.3%的评估被认为支持视觉阅片。
- 披露定量结果后,5名阅片者间一致性改善(基线κ=0.65,65.3%一致;披露后κ=0.74,73.3%一致)。
- 披露定量结果后阅片信心显著增加(基线均值4.0 vs 披露后均值4.34,Wilcoxon统计量W=101,056,P<0.001)。
关键数值与推荐
- Centiloid分类 cutoff=21。
- 局部阅片者信心低定义为5分制≤3分。
- 全队列视觉评估与Centiloid状态一致性κ=0.85,92.3%一致。
- 疑难子样本披露定量前后阅片者间一致性κ=0.65 vs κ=0.74。
- 阅片信心基线均值4.0 vs 披露后均值4.34,P<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several studies have demonstrated strong agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support assessment by less experienced readers or in challenging cases. However, all studies to date have implemented a retrospective case collection, and challenging cases were generally underrepresented. Methods: We included all participants (n = 741) from the AMYPAD diagnostic and patient management study with available baseline amyloid PET quantification. Quantification was done with the PET-only AmyPype pipeline, providing global Centiloid and regional z scores. Visual assessment was performed by local readers for the entire cohort. From the total cohort, we selected a subsample of 85 cases for which the amyloid status based on the local reader's visual assessment and the Centiloid classification (cutoff = 21) was discordant or that were assessed with low confidence (i.e., ≤3 on a 5-point scale) by the local reader. In addition, concordant negative (n = 8) and positive (n = 8) scans across tracers were selected. In this sample (n = 101 cases; [18F]flutemetamol, n = 48; [18F]florbetaben, n = 53), the visual assessments and corresponding confidence by 5 certified independent central readers were captured before and after disclosure of the quantification results. Results: For the whole AMYPAD diagnostic and patient management study cohort, overall assessment by local readers highly agreed with Centiloid status (κ = 0.85, 92.3% agreement). This was consistently observed within disease stages (subjective cognitive decline-plus, κ = 0.82, 92.3% agreement; mild cognitive impairment, κ = 0.80, 89.8% agreement; dementia, κ = 0.87, 94.6% agreement). Across all central reader assessments in the challenging subsample, quantification of global Centiloid and regional z scores was considered supportive of visual reads in 70.3% and 49.3% of assessments, respectively. After disclosure of the quantitative results, we observed improvement in concordance across the 5 readers (baseline κ = 0.65, 65.3% agreement; κ after disclosure = 0.74, 73.3% agreement) and a significant increase in reader confidence (baseline mean (M) = 4.0 vs. M after disclosure = 4.34, Wilcoxon statistic (W) = 101,056, P < 0.001). Conclusion: In this clinical study enriched for challenging amyloid PET cases, we demonstrate the value of quantification to support visual assessment. After disclosure, both interreader agreement and confidence showed significant improvement. These results are important considering the arrival of antiamyloid therapies, which used the Centiloid metric for trial inclusion and target engagement. Moreover, quantification could support determination of amyloid-β status with high certainty, an important factor for treatment initiation.
引用
- Collij LE, Bischof GN, Altomare D, et al. Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study. J Nucl Med. 2025. PMID: 39542700. doi:10.2967/jnumed.124.268119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。